An open-label, multicenter clinical trial to assess the safety and efficacy of three different doses of OPS-2071 in patients with bacterial enteritis

Trial Profile

An open-label, multicenter clinical trial to assess the safety and efficacy of three different doses of OPS-2071 in patients with bacterial enteritis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs OPS 2071 (Primary)
  • Indications Bacterial infections; Enteritis
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Mar 2017.
    • 11 Jul 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top